Showing results (181-190 of 263) with videos related to
Sort By:
Pageof 27
Cancer Research|March 15, 1988
Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancerH I Scher, B Shank, R Chapman, et al.British Journal of Cancer|December 1, 1992
Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolaseT A Splinter, C F Verkoelen, M Vlastuin, et al.American Journal of Clinical Oncology|April 1, 1994
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study GroupT Conroy, P Cappelaere, M Fabbro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implicationsR A Ghossein, H I Scher, W L Gerald, et al.Cancer Chemotherapy and Pharmacology|January 1, 1990
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiencyR J Motzer, D Niedzwiecki, M Isaacs, et al.British Journal of Cancer|September 1, 1996
Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study GroupT C Kok, A Van der Gaast, J Dees, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancerW K Kelly, H I Scher, M Mazumdar, et al.British Journal of Cancer|August 1, 1996
Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centresL G Jørgensen, K Osterlind, J Genollá, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 1999
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancerM C Graham, H I Scher, G B Liu, et al.Seminars in Oncology|March 10, 2001
A potential role for activated HER-2 in prostate cancerD B Agus, R W Akita, W D Fox, et al.Pageof 27